William Blair Has Optimistic Outlook of AWH FY2024 Earnings

Aspira Women’s Health Inc. (NASDAQ:AWH) – Stock analysts at William Blair boosted their FY2024 EPS estimates for shares of Aspira Women’s Health in a research report issued to clients and investors on Tuesday, November 26th. William Blair analyst A. Brackmann now expects that the company will post earnings of ($1.07) per share for the year, up from their previous forecast of ($1.19). The consensus estimate for Aspira Women’s Health’s current full-year earnings is ($1.26) per share. William Blair also issued estimates for Aspira Women’s Health’s Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.57) EPS.

A number of other equities research analysts have also recently commented on AWH. StockNews.com assumed coverage on shares of Aspira Women’s Health in a research report on Monday. They set a “hold” rating for the company. Alliance Global Partners decreased their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Trading Up 6.6 %

AWH opened at $0.81 on Thursday. The firm has a market cap of $13.50 million, a price-to-earnings ratio of -0.68 and a beta of 1.44. Aspira Women’s Health has a 12 month low of $0.67 and a 12 month high of $5.65. The stock has a fifty day moving average price of $0.83 and a 200-day moving average price of $1.27.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co purchased a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned approximately 0.19% of Aspira Women’s Health as of its most recent SEC filing. Hedge funds and other institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.